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In ‘Emotional processing in a ten-session general
psychiatric treatment for borderline personality
disorder: A case study’, the author presents the sit-
uation where, after 10 sessions of a modiﬁed form
of General Psychiatric Management (GPM), the
patient not only fails to improve but actually ap-
pears to be trending in the direction of clinical de-
terioration, especially in her appreciation and
expression of distress. The other two commentar-
ies discuss possible reasons for this lack of im-
provement. I will address a straightforward and
everyday clinical dilemma, i.e. where does the cli-
nician go from here. The patient has not only
failed to make progress but appears to be deterio-
rating. Then what does the clinician do?
The ﬁrst decision point is to call in a colleague
either to consult directly with the patient and the
clinician or for the consultant to have a conversa-
tion with the clinician alone. These are patients
that are not only very difﬁcult to treat, but very
difﬁcult to treat by oneself. Bringing in another
colleague with whom to confer about the case
can add a level of objectivity that perhaps has got-
ten lost or distorted in the complex transferential–
countertransferential situations that often occur in
treatment with these patients (Gabbard &
Wilkinson, 1994; Gunderson, 2001). While
GPM would suggest that the failure to improve is
probably related to an interpersonal ‘event’
between the therapist and the patient (Gunderson
& Links, 2014), it may only be in an open discus-
sion with a non-judgmental colleague that under-
standing more completely what that interpersonal
event could have been might be clariﬁed. A glance
at Figure 2 of the case study would suggest directing
one’s attention to events of sessions 3 through 6
(Berthoud, 2015). After session 3 there was a
deterioration of the working alliance (even if not
statistically signiﬁcant) accompanied by a dramatic
increase in global distress and some increase in fear
and shame. Examining those 4 sessions in more
detail could lead to a better appreciation of what
might have been some of the interpersonal
stressors that perhaps were not seen at that time
they were occurring.
The second decision is whether there should be
some consideration of changing the patient’s phar-
macologic regimen. The author writes ‘Adjunct
pharmacotherapy was used to aid with anxiety
and her difﬁculty sleeping’, but we do not know
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which speciﬁc psychopharmacologic agent(s) were
employed. While there is lack of clarity as to
which pharmacologic agents might be most useful
(and most useful implies moderately effective at
best) in borderline personality disorder (BPD)
(Duggan, Huband, Smailagic, Ferriter, & Adams,
2008; Saunders & Silk, 2009; Stoffers et al.,
2010), this does not mean that one should avoid
psychopharmacology. But it should be used mod-
estly with limited expectations. If there were sleep
disturbances in addition to anxiety, it would in the
long run be wiser clinically if the sleep and the
anxiety could be modiﬁed by a single medication
and preferably not a medication from the benzodi-
azepine or its near-neighbor (i.e. z-drugs) class.
Thus there might be some wisdom in considering
a low-dose of a somewhat sedating atypical antipsy-
chotic (Saunders & Silk, 2009; Silk & Feurino III,
2012). There is some evidence for effectiveness of
aripiprazole (Nickel et al., 2006) or olanzapine
(Zanarini et al., 2012), or, most recently, quetiapine
(Black et al., 2014), in these situations in patients
with BPD. A low-dose atypical antipsychotic might
also help with what was described as ‘schizotypal
traits’. Two caveats are worth mentioning: (1) the
dose used should be low-dose, and (2) only one of
the medications from this class be used. There is
no evidence for the effectiveness of multiple medi-
cations from within the same pharmacologic class
in this diagnostic group. The patient is a young
woman with self-esteem and body-image issues,
and thus one needs to be cognizant of and sensitive
to potential weight gain (Silk, 2011).
Another decision, and one that may be more
complicated than the psychopharmacologic one,
is whether there should be a change in treatment
approach away from GPM or the addition of other
psychotherapeutic interventions to the GPM. The
answer to this question hopefully would be in-
formed by the discussion and consultation with a
colleague as mentioned above. Does the patient
need a therapy even more structured than GPM?
On one hand she appears competent in some areas,
but that competency may at best be a pseudo-
competency, and she may need more coping skills
and more speciﬁc work on cognitive processing
that may be more directly addressed through DBT
(Linehan et al., 2006) or CBT (Davidson et al.,
2006). On the other hand, and this may go back
to appreciating in more detail the interpersonal
events that occurred in the therapy between
sessions 3 and 6, a greater focus on mentalization
may be needed (Bateman & Fonagy, 2008),
either through adding more emphasis on
mentalization in the GPM itself or directing the
patient to a more mentalization-speciﬁc focused
treatment. I would not at this juncture suggest a
transference-focused therapy approach because I
surmise that it is a lack of coping skills and
mentalization that appear to be at the heart of this
woman’s difﬁculties that are most likely being
experienced quite acutely in the therapy but are
probably also experienced more or less intensely
in many situations throughout any given day.
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